Systematic review of 16 studies (Bayesian meta-analysis of randomised trials): in non-urinary S. aureus infections, neither ceftaroline (OR 1.38, 95% CrI 0.81–2.44) nor ceftobiprole (OR 0.99, 0.59–1.62) clearly improved clinical cure vs standard of care; adverse events similar.
Meta-analysisn = 16 studies
Rando et al. Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis